- 1、本文档共7页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Epalrestat alone treatment of diabetic peripheral neuropathy in the literature of_0
PAGE \* MERGEFORMAT 7
Epalrestat alone treatment of diabetic peripheral neuropathy in the literature of
[Abstract] Objective To evaluate the Epalrestat treatment of diabetic peripheral neuropathy, the clinical efficacy and safety. Method to retrieve the China Journal Net (CNKI literature database containing information about Epalrestat treatment of diabetic peripheral neuropathy study, based on inclusion and exclusion standard collection of literature on effectiveness. Results efficacy evaluation were included nine clinical controlled study, efficient Epalrestat group (75.0%) than control group (44.9%). Conclusion epalrestat the treatment of diabetic peripheral neuropathy treatment is effective.
[Keywords:] Epalrestat, diabetes, neuropathy
Epalrestat (Epalrestat) is currently the only listed the aldose reductase inhibitor, reversibly suppressed and the pathogenesis of diabetic complications related to the polyol sorbitol metabolism of glucose into the role of aldose reductase and . This product is from Japan, Ono Pharmaceutical Development, in 1992, first listed in Japan, in 2004 the development of Yangtze River Pharmaceutical Group epalrestat in the domestic market. This product can be used for prevention, and treatment of diabetes mellitus to improve the peripheral nerve disorders ( numbness, pain, vibration, paresthesia, and cardiac anomalies (shown higher glycosylated hemoglobin values. In this study the evaluation, analysis Epalrestat study with the basis, Epalrestat alone in the treatment of diabetic neuropathy side a summary of the literature in order to better illustrate epalrestat clinical efficacy of treatment of diabetic peripheral neuropathy, clinical treatment.
1 study
Between 2004 and 2009 published in the China Journal Net (CNKI the United Epalrestat treatment of diabetic peripheral neuropathy research literature.
2 Methods
2.1 The literature search with “epalrestat” as key words, find the China Journal Net (CNKI database, s
您可能关注的文档
- Enterprises must create a new category of furniture.doc
- Enterprises price promotion how can you ensure that the interests of dealers-.doc
- Enterprises in the marketing process the need to look back.doc
- Enterprises grow up thinking the expense of their own!.doc
- Enterprises need psychological growth class training it-.doc
- Enterprises should have 'big deal' in mind and vision.doc
- Enterprises should not rely on the 'culture' alive.doc
- Enterprises referred to adapt to the requirements of marketing communications.doc
- Enterprises to build two lines.doc
- Enterprises to engage in 'profit sharing marketing' Do not fall into the trap of tax evasion.doc
- 2025年交通行业碳中和目标下的新能源汽车推广策略.docx
- 2025年人工智能在药物研发靶点识别中的机器学习算法研究报告.docx
- 聚焦2025:企业碳排放数据监测与低碳转型策略报告.docx
- 城市公共绿地建设与2025年社区稳定风险防控措施分析报告.docx
- 康复医疗服务行业创新技术应用与产业协同研究报告.docx
- 2025年新能源光伏发电系统科技成果转化项目资金申请策略研究.docx
- 2025年房地产市场成交数据归因:房地产市场调控政策解读与分析报告.docx
- 2025年社区旧衣物回收与跨境再生利用技术创新趋势分析.docx
- 2025年网络直播规范化发展路径与商业模式创新策略分析报告.docx
- 高血压的心血管并发症和康复护理.pptx
文档评论(0)